学术周报 · IF≥10

胃肠外科领域文献阅读汇编

2026年第42周 (2026-10-17) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
10
临床研究
8
基础研究
2
IF≥20
2
IF 10-20
8
子领域
5
期刊种类
9
数据日期
2026-10-17

★本周 Top 10 高影响力文献

#论文期刊IF
1Nivolumab-Ipilimumab for Localized Microsatellite Instability-High Gastric/Gastroesophageal Junction...JAMA oncologyIF 23.9
2A microbial chromatin remodeler drives gastric cancer progression and immune evasion by reprogrammin...Cell host & microbeIF 23.2
3Bariatric Surgery and Risk of Obesity-Related Cancer by Age and Sex.JAMA surgeryIF 15.6
4Integrated Multi-Time-Point 18F-FAPI PET/CT and Immune Histopathology for Predicting Pathological Co...MedCommIF 14.1
5Single-EV MagaDecoder: Combining extracellular vesicles magnetic enrichment and multidimensional bio...Biosensors & bioelectronicsIF 11.8
6Lymph Node Metastasis Mapping after Neoadjuvant Immunochemotherapy in Gastric and Gastroesophageal J...Cancer lettersIF 11.8
7Post-endoscopy upper gastrointestinal cancer in a United States multicenter cohort: site- and risk-s...EndoscopyIF 11.8
8Dielectrophoresis-Assisted PVDF/DES/Au NP-Based Microfluidic ECL Biosensor for In Situ Detection of ...ACS sensorsIF 10.9
9The evolving role of metabolic and bariatric surgery in contemporary clinical practice.European journal of preventive cardiologyIF 10.0
10Extracellular vesicle signature is associated with cardio-metabolic improvement after bariatric surg...European journal of preventive cardiologyIF 10.0

Ŧ期刊分布统计

期刊篇数IF
European journal of preventive cardiology2IF 10.0
ACS sensors1IF 10.9
JAMA oncology1IF 23.9
Biosensors & bioelectronics1IF 11.8
JAMA surgery1IF 15.6
Cell host & microbe1IF 23.2
MedComm1IF 14.1
Cancer letters1IF 11.8
Endoscopy1IF 11.8

1胃癌/胃切除 (3篇)

临床研究 (2篇)

JAMA oncology IF 23.9 2026-10-15 PMID: 42879140
Neoadjuvant nivolumab plus ipilimumab in localized deficient mismatch repair/microsatellite instability-high gastric or gastroesophageal junction (GEJ) adenocarcinoma was evaluated in the NEONIPIGA study. The primary end point of pathological complete response (pCR) was previously reported. To report long-term follow-up results and secondary end points, including event-free survival (EFS) and overall survival (OS), of the NEONIPIGA study. The NEONIPIGA study is a French, multicenter, single-arm, phase 2 nonrandomized clinical trial that included patients with histologically proven cT2-T4NXM0 deficient mismatch repair/microsatellite instability-high GEJ adenocarcinoma who were eligible for surgery. Patients were enrolled between October 23, 2019, and June 4, 2021, and the database was locked on November 13, 2025. Neoadjuvant nivolumab, 240 mg, every 2 weeks for 6 cycles plus ipilimumab, 1 mg/kg, every 6 weeks for 2 cycles, followed by surgery 5 weeks after the last nivolumab dose, and adjuvant nivolumab, 480 mg, every 4 weeks for 9 cycles. EFS and OS. A total of 32 patients (median [range] age, 65 [40-80] years; 8 [28%] female and 21 [72%] were male) were included: 16 (50%) with gastric cancer and 16 (50%) with GEJ cancer. Three patients did not undergo surgery (1 with metastatic disease and 2 who refused). Twenty-seven patients (84%) completed neoadjuvant therapy and 14 (44%) received all treatment as planned. Neoadjuvant and adjuvant therapy-related grade 3/4 adverse events occurred in 6 (19%) and 4 patients (17%), respectively. Median follow-up was 48.3 months (95% CI, 44.8-52.0 months). Among the 32 patients in the intention-to-treat population, 4-year OS was 84.1% (95% CI, 65.8%-93.0%). In the 31 patients eligible for surgery, 4-year EFS was 83.5% (95% CI, 64.8%-92.8%). One patient relapsed with cerebral metastases. Six deaths occurred: 2 related to gastric cancer or treatment (1 patient had postoperative complications and 1 cerebral metastases) and 4 unrelated. All patients who did not undergo surgery achieved a clinical complete response after immune checkpoint inhibitor therapy. One patient subsequently died of causes unrelated to their cancer. Overall, 17 of 29 patients (59%) achieved pCR on surgical specimen. Safety was previously reported, and no additional late toxic effects were observed. In this phase 2 nonrandomized clinical trial, the immunotherapy regimen evaluated was associated with sustained long-term survival, but no clear evidence of improved survival over outcomes reported in other studies evaluating surgery alone in this patient population was observed. The high pCR rates and durable responses observed may provide useful information for designing future clinical studies, including randomized trials investigating organ-preserving strategies. ClinicalTrials.gov Identifier: NCT04006262.
中文摘要:NEONIPIGA研究评估了新辅助纳武利尤单抗联合伊匹木单抗治疗局限性错配修复缺陷/微卫星高度不稳定胃或胃食管结合部腺癌的疗效,主要终点病理完全缓解此前已报道。本报告给出该研究的长期随访结果及次要终点,包括无事件生存和总生存。NEONIPIGA是一项法国多中心、单臂、2期非随机临床试验,纳入组织学证实的cT2-T4NXM0、错配修复缺陷/微卫星高度不稳定、适合手术的胃食管结合部腺癌患者。患者于2019年10月23日至2021年6月4日入组,数据库锁定于2025年11月13日。治疗方案为新辅助纳武利尤单抗240 mg每2周1次共6个周期,联合伊匹木单抗1 mg/kg每6周1次共2个周期,末次纳武利尤单抗后5周手术,术后辅助纳武利尤单抗480 mg每4周1次共9个周期。终点为无事件生存和总生存。共纳入32例患者,中位(范围)年龄65(40-80)岁;女性8例(28%),男性21例(72%);胃癌16例(50%),胃食管结合部癌16例(50%)。3例未接受手术,其中1例为转移性疾病,2例拒绝。27例(84%)完成新辅助治疗,14例(44%)按计划接受全部治疗。新辅助和辅助治疗相关3/4级不良事件分别发生于6例(19%)和4例(17%)。中位随访48.3个月(95%置信区间,44.8-52.0个月)。意向治疗人群32例中,4年总生存率为84.1%(95%置信区间,65.8%-93.0%)。适合手术的31例患者中,4年无事件生存率为83.5%(95%置信区间,64.8%-92.8%)。1例患者复发脑转移。共发生6例死亡:2例与胃癌或治疗相关,其中1例术后并发症、1例脑转移;4例无关。未手术患者均在免疫检查点抑制剂治疗后达到临床完全缓解。1例随后死于与癌症无关的原因。29例手术标本中17例(59%)达到病理完全缓解。安全性此前已报道,未观察到新的迟发毒性反应。在这项2期非随机临床试验中,所评估的免疫治疗方案与持续长期生存相关,但与其他评估该人群单纯手术治疗的研究报告结局相比,未见生存改善的明确证据。观察到的高病理完全缓解率和持久缓解可能为设计未来临床研究提供有用信息,包括探讨保留器官策略的随机试验。ClinicalTrials.gov注册号:NCT04006262。
Cancer letters IF 11.8 2026-10-13 PMID: 42869124
Although neoadjuvant immunochemotherapy (NICT) has improved survival in locally advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC), lymph node metastasis (LNM) patterns following NICT remain undefined. We aimed to characterize topographical LNM patterns after NICT and evaluate the association between lymphadenectomy extent, surgical approach, and survival outcomes. Data were pooled from 4 prospective clinical trials (NEOSUMMIT-01 - 04), comprising 126 patients with GC (n = 61) or GEJC (n = 65) undergoing curative gastrectomy following NICT. ypN0 was achieved in 71 patients (56%). In GEJC, station No. 3, 7 were high risk; No. 1, 2, 9, and 11 were intermediate risk; and No. 4, 5, 6, 8, 12 were low risk. In GC, station No. 12 was low-risk; D1 stations (No. 1, 3, 4, 5, 6, 7) were high-risk, D1+ stations (No. 8, 9) and No. 11 were intermediate-risk. At a median follow-up of 36.2 months, 24-month EFS and OS rates were 76.4% and 90.5%. Nodal yield (≥ 30 vs. < 30) was not significantly associated with EFS (P = .611) or OS (P = .911). In exploratory comparisons within the GEJC cohort, EFS (P = .219) and OS (P = .290) did not differ significantly between proximal and total gastrectomy. In GEJC, distal perigastric lymph node stations (No. 4, 5, 6, and 12) exhibited low metastasis rates, while exploratory survival outcomes support prospective clinical trials of proximal gastrectomy in appropriately selected patients. Conversely, the broader residual nodal involvement in GC reinforces the continued role of standard D2 lymphadenectomy.
中文摘要:新辅助免疫化疗(NICT)改善了局部进展期胃癌(GC)和胃食管结合部癌(GEJC)的生存,但NICT后的淋巴结转移(LNM)模式仍未明确。本研究旨在描述NICT后淋巴结转移的分布特征,并评估淋巴结清扫范围、手术方式与生存结局之间的关联。数据汇总自4项前瞻性临床试验(NEOSUMMIT-01至04),共纳入126例接受NICT后根治性胃切除的患者,其中GC 61例、GEJC 65例。71例(56%)达到ypN0。在GEJC中,第3、7站为高风险,第1、2、9、11站为中风险,第4、5、6、8、12站为低风险。在GC中,第12站为低风险,D1站(第1、3、4、5、6、7站)为高风险,D1+站(第8、9站)及第11站为中风险。中位随访36.2个月,24个月无事件生存(EFS)率和总生存(OS)率分别为76.4%和90.5%。淋巴结检出数(≥30枚与<30枚)与EFS(P=.611)或OS(P=.911)无显著关联。在GEJC队列的探索性比较中,近端胃切除与全胃切除的EFS(P=.219)和OS(P=.290)差异无统计学意义。在GEJC中,远端胃周淋巴结站(第4、5、6、12站)转移率低,探索性生存结果支持在合适选择的患者中开展近端胃切除的前瞻性临床试验。相反,GC中较广泛的残留淋巴结受累支持继续采用标准D2淋巴结清扫。

基础研究 (1篇)

Cell host & microbe IF 23.2 2026-10-14 PMID: 42705235
First-line treatment for gastric cancer (GC) includes PD-1 blockade with chemotherapy, but resistance challenges treatment success. We identify Streptococcus anginosus (SA) as a tumor-resident oncobacterium driving GC progression and immune evasion. SA is enriched in GC patient tumors and drives tumor growth in mice. SA extracellular vesicles (saEVs) translocate the bacterial chromatin remodeler saSNF2 into host cells. saSNF2 partners with host transcription factor TEAD1-through its ATPase activity and participation in BRG1/BRM-associated factor (BAF) complex assembly-to activate oncogenic transcription. This transkingdom interaction upregulates the palmitoyltransferase ZDHHC11, which stabilizes PD-L1 via palmitoylation to establish an immunosuppressive niche, while amplifying other TEAD1 target genes to fuel tumor progression. saEVs promote tumor growth and limit CD8+ T cell infiltration in vivo. Pharmacological inhibition of ZDHHC11 reverses immune evasion and synergizes with anti-PD-1 checkpoint blockade. These findings establish SA as a multifaceted driver of GC and highlight the saSNF2-ZDHHC11 axis as a target to potentiate immunotherapy.
中文摘要:胃癌一线治疗包括PD-1阻断联合化疗,但耐药使治疗难以成功。研究鉴定出咽峡炎链球菌(SA)为定植于肿瘤的致癌细菌,驱动胃癌进展与免疫逃逸。SA在胃癌患者肿瘤中富集,并在小鼠体内驱动肿瘤生长。SA胞外囊泡(saEVs)可将细菌染色质重塑蛋白saSNF2转运入宿主细胞。saSNF2借助其ATP酶活性并参与BRG1/BRM相关因子(BAF)复合物组装,与宿主转录因子TEAD1协同激活致癌转录。这种跨界相互作用上调棕榈酰转移酶ZDHHC11,后者通过棕榈酰化稳定PD-L1,形成免疫抑制微环境,同时放大其他TEAD1靶基因以推动肿瘤进展。体内实验中saEVs促进肿瘤生长并限制CD8+ T细胞浸润。药理学抑制ZDHHC11可逆转免疫逃逸,并与抗PD-1检查点阻断产生协同作用。这些结果确立SA为胃癌的多重驱动因素,并提示saSNF2-ZDHHC11轴是增强免疫治疗的靶点。

2减重/代谢手术 (3篇)

临床研究 (3篇)

JAMA surgery IF 15.6 2026-10-14 PMID: 42873495
Obesity is associated with elevated risks for multiple cancers. How bariatric surgery influences these risks across age and sex is insufficiently understood. To evaluate the association between bariatric surgery and obesity-related cancer (breast, endometrial, ovarian, esophageal adenocarcinoma, liver, pancreatic, colon, rectal, kidney, and multiple myeloma) and whether this association varies by age and sex. This population-based cohort study within the Nordic Obesity Surgery Cohort (NordOSCo) included individuals aged 18 to 59 years with an obesity record in Denmark, Finland, or Sweden from 1992 to 2023. Prospectively collected data on exposure, outcomes, and confounders were obtained from well-maintained national registries. Follow-up continued until cancer diagnosis, death, emigration, or December 31, 2023. These data were analyzed from December 2025 to April 2026. Bariatric surgery vs no surgery among individuals with obesity. The primary outcome was incidence of obesity-related cancers. Risks were compared using crude and multivariable-adjusted incidence rate ratios (aIRR) with 95% CIs derived from Poisson regression adjusted for age, sex, calendar year, country, and obesity- and lifestyle-related comorbidities. Effect modification by age group (18-39 vs 40-59 years) and sex (female vs male) was evaluated using interaction terms. Among 784 105 individuals with obesity (569 266 women [73%] and 214 839 men [27%]), 99 614 underwent bariatric surgery. Surgery was associated with a lower risk of obesity-related cancer overall (aIRR, 0.81; 95% CI, 0.77-0.85). The magnitude of risk reduction did not differ by age group (individuals aged 18 to 39 years: aIRR, 0.80; 95% CI, 0.72-0.88 and individuals aged 40 to 59 years: aIRR, 0.81; 95% CI, 0.78-0.86) (P for interaction = .88). Associations for non-sex-specific cancers were similar in men and women (P for interaction = .50). For individual cancers, the strongest inverse associations were observed for liver cancer (aIRR, 0.49; 95% CI, 0.34-0.70), endometrial cancer (aIRR, 0.51; 95% CI, 0.45-0.59), and ovarian cancer (aIRR, 0.73; 95% CI, 0.60-0.87). In contrast, pancreatic cancer risk was increased after surgery, particularly among younger adults (aIRR, 2.21; 95% CI, 1.44-3.39; P = .01). In this study, bariatric surgery was associated with a lower long-term risk of obesity-related cancers, with similar associations across age groups and sexes. These findings suggest that the long-term oncologic benefits of bariatric surgery apply broadly across age groups and sexes, supporting equitable access to bariatric surgery for patients with obesity.
中文摘要:肥胖与多种癌症风险升高相关。减重手术如何在不同年龄与性别中影响这些风险,目前了解不足。研究旨在评估减重手术与肥胖相关癌症(乳腺癌、子宫内膜癌、卵巢癌、食管腺癌、肝癌、胰腺癌、结肠癌、直肠癌、肾癌及多发性骨髓瘤)之间的关联,并检验该关联是否随年龄和性别而变化。这项基于人群的队列研究依托北欧肥胖手术队列(NordOSCo),纳入1992年至2023年在丹麦、芬兰或瑞典有肥胖记录的18至59岁个体。暴露、结局与混杂因素数据均为前瞻性收集,来自维护良好的国家登记数据库。随访持续至癌症确诊、死亡、移居或2023年12月31日。数据分析时间为2025年12月至2026年4月。暴露为肥胖个体中接受减重手术与未接受手术的比较。主要结局为肥胖相关癌症的发病。采用泊松回归计算粗率比和多变量校正发病率比(aIRR)及95%CI,校正年龄、性别、日历年份、国家以及肥胖与生活方式相关合并症。通过交互项评估年龄组(18-39岁与40-59岁)和性别(女性与男性)的效应修饰。784 105名肥胖个体中(女性569 266人[73%],男性214 839人[27%]),99 614人接受了减重手术。手术与肥胖相关癌症总体风险降低相关(aIRR 0.81;95%CI 0.77-0.85)。风险降低幅度在不同年龄组间无差异(18-39岁:aIRR 0.80;95%CI 0.72-0.88;40-59岁:aIRR 0.81;95%CI 0.78-0.86)(交互作用P=0.88)。非性别特异性癌症的关联在男女间相似(交互作用P=0.50)。就各具体癌症而言,最强负相关见于肝癌(aIRR 0.49;95%CI 0.34-0.70)、子宫内膜癌(aIRR 0.51;95%CI 0.45-0.59)和卵巢癌(aIRR 0.73;95%CI 0.60-0.87)。相反,术后胰腺癌风险升高,在较年轻成人中尤为明显(aIRR 2.21;95%CI 1.44-3.39;P=0.01)。本研究中,减重手术与肥胖相关癌症的长期风险降低相关,且这一关联在各年龄组和性别间相似。这些结果提示减重手术的长期肿瘤学获益在年龄组和性别间广泛适用,支持肥胖患者公平获得减重手术。
European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 41453132
Metabolic and bariatric surgery (MBS) has long been considered the most effective long-term treatment for severe obesity and its associated comorbidities, including type-2 diabetes mellitus, metabolic syndrome, obstructive sleep apnoea syndrome, and cardiovascular disease. Beyond weight loss, MBS has been associated with improved glycaemic and metabolic control, lower apnoea burden, reduced risk of major adverse cardiovascular events, and improved overall survival. In the last few years, the use of safe and effective weight-loss medications has revolutionized the management of patients with obesity, and may in the future influence referral patterns for MBS. Future research is therefore warranted to clarify the integration between MBS and these novel pharmacological opportunities, with the aim of optimizing patient selection and therapeutic pathways. The aim of this narrative review is therefore to describe the role of MBS in contemporary clinical practice, considering the evolving landscape of pharmacological approaches to treat patients with obesity.
中文摘要:代谢与减重手术(MBS)长期被视为重度肥胖及其相关合并症(包括2型糖尿病、代谢综合征、阻塞性睡眠呼吸暂停综合征和心血管疾病)最有效的长期治疗手段。除减轻体重外,MBS还与血糖和代谢控制改善、呼吸暂停负担降低、主要不良心血管事件风险下降以及总体生存率提高相关。近几年,安全有效的减重药物改变了肥胖患者的管理方式,未来可能影响MBS的转诊模式。因此,未来研究需要明确MBS与这些新型药物治疗机会的整合方式,以优化患者选择和治疗路径。本叙述性综述旨在描述MBS在当代临床实践中的作用,并考虑肥胖药物治疗不断演变的格局。
European journal of preventive cardiology IF 10.0 2026-10-13 PMID: 40911403
Bariatric surgery (BS) reduces obesity-associated systemic inflammation leading to multiple cardiovascular (CV) and metabolic benefits. Here, we tested whether measuring vaso-inflammatory cytokines, gut hormones, and circulating extracellular vesicles (EV) provide vaso-inflammatory-metabolic signatures that better correlate to CV-metabolic outcomes after BS, compared to a standard clinical assessment including body weight (BW) loss and traditional CV risk factors. In 111 patients with severe obesity, conventional clinical-biochemical parameters and non-conventional vaso-inflammatory-metabolic markers were analysed at baseline, after 1- (T12) and 3-years (T36) post-BS and were associated to post-surgical BW loss and improvement of patients' CV-metabolic profile. Body weight decreased from a median of 111 to 77 Kg at T36 (30 Kg and 32.8% BMI cumulative reduction), and all traditional CV risk factors improved after BS. However, the baseline evaluation of these parameters was unable to discriminate patients according to their CV-metabolic outcome, after BS. This objective was achieved combining the decrease in circulating serum amyloid associated protein, IL-6, TNF-α, and insulin after BS, together with the increase of GLP-1, ghrelin, PYY and bile acids, and changes in EV profiling. Of note, a specific signature given by the reduced expression of several surface antigens carried by EVs and specific single EV markers (i.e. derived from endothelium, platelets, inflammatory cells), successfully discriminated patients at baseline according to their CV-metabolic post-surgical outcome. Non-conventionally measured vaso-inflammatory-metabolic signatures, and in particular EV profiling, are associated with CV-metabolic outcome after BS and may be integrated to conventional parameters to improve the management and risk stratification of these patients.
中文摘要:减重手术(BS)可减轻肥胖相关系统性炎症,带来多方面心血管(CV)和代谢获益。本研究检验检测血管炎症细胞因子、肠道激素和循环细胞外囊泡(EV)所得到的血管炎症代谢特征,是否较包括体重下降和传统CV危险因素的标准临床评估,更能与BS后CV代谢结局相关。在111例重度肥胖患者中,于基线、BS后1年(T12)和3年(T36)分析常规临床生化参数和非传统血管炎症代谢标志物,并将其与术后体重下降及患者CV代谢谱改善相关联。体重中位数从111 kg降至T36的77 kg(累计下降30 kg,BMI累计下降32.8%),所有传统CV危险因素在BS后均改善。然而,基线时评估这些参数无法按BS后CV代谢结局区分患者。联合BS后循环血清淀粉样相关蛋白、IL-6、TNF-α和胰岛素下降,GLP-1、胃饥饿素、PYY和胆汁酸升高,以及EV谱变化,可实现这一目标。一种特定特征由EV携带的多种表面抗原表达降低及特定单一EV标志物(如来源于内皮、血小板、炎症细胞)构成,能够在基线时成功区分患者术后CV代谢结局。非传统测量的血管炎症代谢特征,尤其EV谱,与BS后CV代谢结局相关,可能与传统参数整合,以改善这些患者的管理和风险分层。

3胃癌 (2篇)

临床研究 (1篇)

Biosensors & bioelectronics IF 11.8 2026-10-15 PMID: 42214853
The information regarding tumor cells, the immune environment and microorganisms can provide insights into the formation and progression of gastric cancer (GC) from various perspectives. However, there remains a need for a diagnostic strategy capable of integrating and analyzing these multiple dimensions to accurately assess the progression of GC. Extracellular vesicles (EVs), which carry multidimensional information, represent a promising non-invasive biomarker for the diagnosis and monitoring of GC. Despite their potential, the development of an efficient method for the enrichment and precise analysis of individual EVs remains a significant challenge. Herein, we present a versatile droplet digital assay, termed the Single-EV MagaDecoder, designed to enable both the enrichment of EVs and the decoding of individual EVs. This assay consisted of two main components: efficient reversible magnetic enrichment of EVs and single EV multidimensional biomarker decoding analysis. To evaluate the clinical utility of the single-EV MagaDecoder for GC diagnosis, screening (n = 64) and validation (n = 79) GC cohorts were utilized. This assay demonstrated exceptional performance in predicting gastric disease risk, achieving 100% accuracy, and distinguishing between benign and malignant conditions with an area under the curve (AUC) of 0.8875. These results were obtained through the detection of multidimensional signatures of GC-EVs in a validation cohort (n = 79). In summary, this study proposes a promising strategy for the precise analysis of multidimensional EV subpopulations at single EV level, thereby advancing the field of precision medicine for GC.
中文摘要:肿瘤细胞、免疫环境和微生物相关信息可从多个角度揭示胃癌的发生与进展。仍需一种能够整合并分析这些多维信息、准确评估胃癌进展的诊断策略。细胞外囊泡(EVs)携带多维信息,是用于胃癌诊断和监测的有前景的无创生物标志物。尽管具有潜力,建立高效富集并精准分析单个EV的方法仍是重大挑战。研究提出一种多功能液滴数字检测方法,称为Single-EV MagaDecoder,旨在实现EV富集和单个EV解码。该检测由两部分组成:高效可逆的EV磁富集和单个EV多维生物标志物解码分析。为评估Single-EV MagaDecoder用于胃癌诊断的临床价值,研究使用胃癌筛查队列(n=64)和验证队列(n=79)。该检测在预测胃部疾病风险方面表现优异,准确率达100%,区分良恶性病变的曲线下面积(AUC)为0.8875。这些结果来自验证队列(n=79)中胃癌EV多维特征的检测。该研究提出一种在单EV水平精准分析多维EV亚群的有前景策略,推动胃癌精准医学发展。

基础研究 (1篇)

ACS sensors IF 10.9 2026-10-16 PMID: 42887006
Herein, a regenerable dielectrophoresis (DEP)-assisted microfluidic electrochemiluminescence (ECL) biosensor was developed for in situ detection of extracellular vesicles (EVs) in gastric cancer ascites. In the integrated microfluidic ECL sensor, a poly(vinylidene fluoride-co-hexafluoropropylene) (PVDF-HFP)/deep eutectic solvent (DES)/Au NP (PDES/Au NPs) self-supporting electrode was developed. The DES treatment increased the polar β-phase proportion in PVDF-HFP and improved its conductivity. Meanwhile, Au NPs deposited on the electrode surface amplified the ECL signal of Ru(bpy)32+/TPrA@SiO2 nanobeads through the localized surface plasmon resonance (LSPR) effect and generated an inhomogeneous electric field distribution for EV capture. Due to the DEP effect, the polarized EVs migrated and enriched on the PDES/Au NP electrode surface. As a result, the isolation time of EVs was reduced from 120 to 30 min. Consequently, the sensing platform effectively captured and detected EVs in gastric cancer ascites. The detection range was 1.0 × 101.6-1.0 × 105.3 particles μL-1, and the limit of detection was 9 particles μL-1. Moreover, a regenerative strategy was designed by controllably cleaving Au-S bonds on the self-supporting electrode. This developed microfluidic ECL biosensor achieved real-time quantification of low-concentration EVs in ascites, which established a promising analytical tool for gastric cancer diagnosis as well as the discrimination of peritoneal metastatic lesions.
中文摘要:构建了一种可再生介电泳辅助微流控电化学发光生物传感器,用于胃腹水中细胞外囊泡的原位检测。在该集成微流控电化学发光传感器中,研制了聚偏氟乙烯-六氟丙烯共聚物/低共熔溶剂/金纳米粒子自支撑电极。低共熔溶剂处理提高了聚偏氟乙烯-六氟丙烯中共聚物极性β相的比例并改善了其导电性。沉积于电极表面的金纳米粒子通过局域表面等离子体共振效应增强Ru(bpy)32+/TPrA@SiO2纳米球的电化学发光信号,并形成非均匀电场分布以捕获细胞外囊泡。在介电泳作用下,极化的细胞外囊泡迁移并富集于电极表面,使细胞外囊泡的分离时间由120分钟缩短至30分钟。该传感平台可有效捕获并检测胃癌腹水中的细胞外囊泡,检测范围为1.0×101.6~1.0×105.3个粒子每微升,检出限为9个粒子每微升。另设计了一种通过可控断裂自支撑电极上Au-S键实现再生的策略。该微流控电化学发光生物传感器实现了腹水中低浓度细胞外囊泡的实时定量,为胃癌诊断及腹膜转移病灶的判别提供了有前景的分析工具。

4直肠癌/TME (1篇)

临床研究 (1篇)

MedComm IF 14.1 2026-10 PMID: 42872124
Predicting pathological complete response (pCR) after neoadjuvant short-course radiotherapy combined with immunotherapy and chemotherapy remains challenging in microsatellite-stable (MSS) locally advanced rectal cancer. In this prospective exploratory study (ClinicalTrials.gov identifier: NCT06608537), 49 patients received short-course radiotherapy followed by sintilimab plus CAPOX and subsequently underwent radical surgery. We investigated whether treatment response could be better characterized by integrating two complementary biological dimensions: baseline immune organization and treatment-related stromal remodeling captured by multi-time-point 1 8F-FAPI PET/CT. The pCR rate was 49.0% (24/49), and serial 1 8F-FAPI imaging revealed distinct stromal kinetic patterns between response groups. Integration of intratumoral tertiary lymphoid structure (iTLS) count, B-cell density, preoperative tumor-to-iliacus muscle ratio (TIMR) at 30 min, and the delayed TIMR retention index from 90 to 120 min (RI34) yielded a four-variable model with a mean AUC of 0.874 in repeated nested cross-validation. Complementary preclinical experiments provided functional support for a CAF-TGFβ-B-cell/TLS axis linking stromal regulation, immune organization, and treatment resistance. These findings highlight the complementary value of spatial immune organization and dynamic FAPI-defined stromal kinetics and provide a biologically informed framework for post-neoadjuvant, preoperative response stratification, pending prospective multicenter validation.
中文摘要:在微卫星稳定(MSS)局部进展期直肠癌中,新辅助短程放疗联合免疫治疗与化疗后预测病理完全缓解(pCR)仍有难度。这项前瞻性探索性研究(ClinicalTrials.gov 注册号 NCT06608537)纳入49例患者,行短程放疗后接受信迪利单抗联合CAPOX方案,随后行根治性手术。研究考察能否通过整合两个互补的生物学维度更好地刻画治疗反应:基线免疫组织状态,以及多时间点18F-FAPI PET/CT所反映的治疗相关间质重塑。pCR率为49.0%(24/49),系列18F-FAPI显像显示不同反应组之间的间质动力学模式存在差异。将瘤内三级淋巴结构(iTLS)计数、B细胞密度、术前30分钟肿瘤与髂肌摄取比(TIMR)以及90至120分钟的延迟TIMR滞留指数(RI34)整合,构建出四变量模型,在重复嵌套交叉验证中平均AUC为0.874。补充的临床前实验为一条连接间质调控、免疫组织与治疗耐药的CAF-TGFβ-B细胞/TLS轴提供了功能学支持。上述结果提示空间免疫组织与FAPI动态间质动力学具有互补价值,并为新辅助治疗后、术前的反应分层提供了有生物学依据的框架,尚待前瞻性多中心验证。

5上消化道癌 (1篇)

临床研究 (1篇)

Endoscopy IF 11.8 2026-10-13 PMID: 42664999
Post-endoscopy upper gastrointestinal cancer (PEUGIC) is an emerging quality metric, but varying definitions complicate benchmarking. We characterized PEUGIC rates and outcomes by anatomic site and coded high-risk condition (HRC) status in a large US cohort. This was a retrospective cancer-first cohort study of 14 814 patients with upper gastrointestinal cancer (UGIC) from a multicenter database (2016-2024). Index endoscopy-detected UGIC was diagnosed within 6 months of esophagogastroduodenoscopy. PEUGIC was defined as UGIC diagnosed 6-36 months after a nondiagnostic esophagogastroduodenoscopy. The primary outcome was PEUGIC rate by cancer type and HRC status. Secondary outcomes included 3-year overall survival. The overall PEUGIC rate was 9.4% (esophageal cancer 9.6%, gastric cancer 8.6%, duodenal cancer 10.7%). Rates were higher with HRC (18.2%) than without HRC (5.0%; P < 0.001). PEUGIC rate without HRC plateaued (4.0%-5.1% in 2022-2024), while PEUGIC rate with HRC for esophageal cancer (16.8%) and gastric cancer (14.4%) decreased over time. In exploratory analysis, PEUGIC was associated with better survival vs. index endoscopy-detected UGIC for esophageal cancer (adjusted hazard ratio [aHR] 0.82, 95%CI 0.67-0.99) and gastric cancer (aHR 0.77, 0.62-0.96), and PEUGIC with HRC was associated with lower mortality vs. PEUGIC without HRC for esophageal cancer (aHR 0.51, 0.36-0.74) and gastric cancer (aHR 0.50, 0.34-0.73). 1 in 10 UGIC patients had a prior nondiagnostic endoscopy within 3 years. PEUGIC rates varied by anatomic site and HRC status, suggesting site- and HRC-stratified benchmarks may better capture endoscopic performance than aggregate metrics.
中文摘要:内镜后上消化道癌(PEUGIC)正成为新兴质量指标,但定义不一使基准比较复杂。研究在美国大型队列中按解剖部位和编码高危疾病状态描述PEUGIC发生率及结局。这是一项回顾性队列研究,以癌症病例为起点,纳入多中心数据库2016—2024年14814例上消化道癌患者。索引内镜检出上消化道癌指食管胃十二指肠镜检查后6个月内诊断。PEUGIC指非诊断性食管胃十二指肠镜检查后6至36个月诊断的上消化道癌。主要结局为按癌种和高危疾病状态划分的PEUGIC发生率,次要结局包括3年总生存。总体PEUGIC发生率为9.4%(食管癌9.6%,胃癌8.6%,十二指肠癌10.7%)。有高危疾病状态者发生率18.2%,高于无高危疾病状态者5.0%(P<0.001)。无高危疾病状态者PEUGIC发生率趋于平台(2022—2024年为4.0%—5.1%),而有高危疾病状态的食管癌(16.8%)和胃癌(14.4%)PEUGIC发生率随时间下降。探索性分析中,食管癌PEUGIC与索引内镜检出上消化道癌相比生存更好(校正风险比[aHR]0.82,95%CI 0.67—0.99),胃癌亦然(aHR 0.77,0.62—0.96);有高危疾病状态的PEUGIC较无高危疾病状态者死亡风险更低,食管癌aHR 0.51(0.36—0.74),胃癌aHR 0.50(0.34—0.73)。约十分之一上消化道癌患者在3年内有既往非诊断性内镜。PEUGIC发生率随解剖部位和高危疾病状态而异,提示按部位和高危疾病状态分层的基准可能比汇总指标更好反映内镜表现。